search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Pilot study added value intermittent vacuum therapy (IVT) in the treatment of intermittent claudication


- candidate number27089
- NTR NumberNTR6353
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR13-apr-2017
- Secondary IDsNL54340.100.15 CCMO
- Public TitlePilot study added value intermittent vacuum therapy (IVT) in the treatment of intermittent claudication
- Scientific TitlePilot study added value intermittent vacuum therapy (IVT) in the treatment of intermittent claudication
- ACRONYMPILOT VACUMED
- hypothesis
- Healt Condition(s) or Problem(s) studiedPeripheral Arterial Disease, Intermittent claudication
- Inclusion criteria-Conservative treatment with supervised exercise therapy (SET)
-Sufficient additional insurance or sufficient financial resources for a SET program of 1 year
-Sufficiently motivated to participate in the study (particularly additional (travel) time investment for treatment with IVT)
-Informed consent
- Exclusion criteria-Maximal walking distance >1000 meters at baseline
-Inability to complete 12 IVT sessions in first 12 weeks (vacation)
-Previous treatment for PAD in the past 2 years (conservative and/or invasive technique)
-Prior treatment with IVT (possibly for other indications than PAD)
-Cognitive disabilities
-Inadequate control of the Dutch language
-Contraindications for IVT (pregnancy, infection and/or inflammation of the lower limb(s), abdominal wall hernia)
-Critical limb ischemia
-Recent (<6 weeks) trauma of the lower limb(s)
-Severe cox- or gonarthrosis and planned joint replacement therapy
- mec approval receivedyes
- multicenter trialyes
- randomisedyes
- masking/blindingDouble
- controlPlacebo
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-dec-2015
- planned closingdate1-jul-2017
- Target number of participants80
- Interventions80 patients divided into 2 groups of 40 patients. Group 1: patients receive a SET program during 1 year supplemented with real IVT in weeks 1 till 12. Group 2: patients receive a SET program during 1 year supplemented with sham (placebo) IVT in weeks 1 till 12.
- Primary outcomeMaximal walking distance, measured by a standardized treadmill test
- Secondary outcome-Functional walking distance, measured by a standardized treadmill test
-Walking distance, measured by a six-minute walk test
-General quality of life, measured by a EQ-5D questionnaire
-Disease-specific quality of life, measured by a VascuQol questionnaire
-Walking impairment, measured by a WIQ questionnaire
- TimepointsBaseline, 6 weeks, 3 months, 6 months and 1 year
- Trial web site
- statusopen: patient inclusion
- CONTACT FOR PUBLIC QUERIESProf. MD PhD, vascular surgeon Joep A.W. Teijink
- CONTACT for SCIENTIFIC QUERIESProf. MD PhD, vascular surgeon Joep A.W. Teijink
- Sponsor/Initiator Catharina Hospital Eindhoven
- Funding
(Source(s) of Monetary or Material Support)
- Publications
- Brief summaryThe preferred treatment for patients with intermittent claudication (IC) is supervised exercise therapy (SET) supplemented with secondary risk prevention. Since 2015, intermittent vacuum therapy (IVT) is intensively promoted in the Netherlands as a minimally invasive treatment for IC. IVT implies that a patient is placed in a tubular device and undergoes periods of negative pressure applied to the lower body, assumed to stimulate leg circulation. A literature search revealed no hard evidence to substantiate the proposed mechanisms of action. Aim of this multicenter randomized controlled trial is to determine a potentially additional effect of IVT on walking distance and health-related quality of life in patients with IC who are treated with a SET program.
At three vascular surgery outpatients clinics, 80 patients with symptomatic IC, based on a < 0.9 rest ankle-brachial index (ABI) or a > 0.15 ABI drop after exercise, are randomized to two treatment arms of 40 patients. Both groups receive standard conservative management for IC including cardiovascular risk management and a SET program of one year. In addition, the experimental group (“IVT”) receives IVT treatment with a negative pressure of -50 mBar, whereas the control group (“Sham”) receives IVT treatment with a negative pressure of -5 mBar. IVT is provided during twelve 30 minute sessions over a six weeks period. Patients and SET-providing physiotherapists are blinded for the given treatment.
Primary outcome measure is the maximal walking distance (standardized treadmill test). Secondary outcome measures are the functional walking distance (standardized treadmill test), walking distance (six-minute walk test), general quality of life (EQ-5D questionnaire), disease-specific quality of life (VascuQol questionnaire) and walking impairment (WIQ questionnaire). Outcomes are assessed at baseline and after 6 weeks, 3 months, 6 months and 1 year.
- Main changes (audit trail)
- RECORD13-apr-2017 - 11-jun-2017


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl